Table 3.

Trials for grade III and high-risk grade II gliomas

Trial	Phase	Tumor histology	Criteria for high-risk	Treatment regimen	OS	PFS	Prolonged survival
RTOG 9802 52 , 53	III	Grade II O, OA, A	≤39 years and subtotal resection/biopsy or ≥40 years	RT (54 Gy) followed by PCV(X6)* vs RT (54 Gy) alone	13.3 years vs 7.8 years	10.4 years vs 4.0 years	10 year survival 62% vs 41%
RTOG 0424 54	II	Grade II O, OA, A	3 of the following features: ≥40 years old, astrocytic features in the histology, bihemispheric tumor, ≥6cm preoperative tumor size, preoperative ECOG performance status >1	RT (50.4 Gy) with concomitant TMZ followed by adjuvant TMZ (X12)**	NA	NA	3 year survival 73.1%
RTOG 9402 46 , 49	III	Grade III AO, AOA	Not applicable	PCV (X4) followed by RT (50.4 Gy) vs RT (50.4 Gy)	Overall group 4.6 years vs 4.7 years 1p19q codeleted population 14.7 years vs 7.3 years	2.6 years vs 1.7 years	NA
EORTC 2695147 47 , 48	III	Grade III AO	Not applicable	RT (59.4 Gy) followed by PCV (X6) vs RT (59.4 Gy)	Overall group 43.2 months vs 30.6 months 1p19q codeleted population Not yet reached vs 112 months	156 months vs 50 months	5 year survival 43.4% vs 37.0%

OS, overall survival; PFS, progression free survival; O, oligodendroglioma; OA, oligoastrocytoma; A, astrocytoma; RT, radiotherapy; PCV, procarbazine, CCNU, vincristine; TMZ, temozolomide; NA, not available; AO, anaplastic oligodendroglioma; AOA, anaplastic oligoastrocytoma.

*PCV [CCNU 110mg/m² D#1, vincristine 1.4mg/m² D#8 and D#29, procarbazine 60mg/m2 D#8–21] was administered over 8 week cycles; **TMZ 75mg/m² during RT followed by 150-200mg/m² /day for 5/28 days; ***PCV [CCNU 130mg/m² D#1, vincristine 1.4mg/m² D#8 and D#29, procarbazine 60mg/m² D#8–21] was administered over 6 week cycles, ****PCV [CCNU 110mg/m² D#1, vincristine 1.4mg/m² D#8 and D#29, procarbazine 60mg/m² D#8–21] was administered over 6 week cycles.